Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-137447

Published: 2020

Journal Articles

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Tea Pemovska, PhD, Gregory Ian Vladimer, PhD, Vitaly Sedlyarov, PhD, Emir Hadzijusufovic, DVM, Karoline Veronika Gleixner, MD, Alexandra Keller, MSc, Berend Snijder, PhD, Nikolaus Krall, PhD, Oscar Lopez de la Fuente, BSc, Mathias A Schneeweiss, MD, Wolfgang R. Sperr, MD, Paul Knöbl, MD PhD, Klaus Geissler, MD, Philipp Bernhard Staber, MD PhD, Ulrich Jaeger, MD, Peter Valent, MD, Giulio Superti Furga, PhD

Blood (2017) 130 (Supplement 1): 4227.

https://doi.org/10.1182/blood.V130.Suppl_1.4227.4227

Published: 2017

Journal Articles

Distinct Diagnostic and Clinical Features of Bone Marrow Mastocytosis: A Study of the Registry of the European Competence Network on Mastocytosis (ECNM)

Massimiliano Bonifacio, MD, Patrizia Bonadonna, MD, Hanneke Oude Elberink, MD, Björn van Anrooij, MD, Aleksandra Górska, MD, Magdalena Lange, MD, Emir Hadzijusufovic, DVM, Luigi Scaffidi, Ilaria Tanasi, MD, Cecelia Perkins, Virginia Valeria Ferretti, Anja Illerhaus, PhD, Thilo Jakob, MD, Roberta Parente, MD, Mohamad Jawhar, MD, Francesca Caroppo, MD, Alexander Zink, MD, Alex Kilbertus, MD, Akif Selim Yavuz, MD, Michael Doubek, MD PhD, Hans Hagglund, MD PhD, Jens P. Panse, MD, Vito Sabato, MD PhD, Elisabeth Aberer, MD, Nadja Jaekel, MD, Peter Vandenberghe, MD PhD, David Fuchs, MD, Knut Brockow, MD, Anna Belloni Fortina, MD, Andreas Reiter, MD, Massimo Triggiani, MD, Khalid Shoumariyeh, MD, Karin Hartmann, MD, Chiara Elena, Olivier Hermine, MD PhD, Jason Gotlib, MD, Marek Niedoszytko, MD, Hanneke Kluin-Nelemans, MD PhD, Wolfgang R. Sperr, MD, Peter Valent, MD, Roberta Zanotti, MD

Blood (2017) 130 (Supplement 1): 4200.

https://doi.org/10.1182/blood.V130.Suppl_1.4200.4200

Published: 2017

Journal Articles

Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy

Emir Hadzijusufovic, DVM, Gregor Hoermann, MD, Susanne Herndlhofer, Wolfgang R. Sperr, MD, Bernd Jilma, MD, Gerit H. Schernthaner, MD, Peter Valent, MD

Blood (2017) 130 (Supplement 1): 1619.

https://doi.org/10.1182/blood.V130.Suppl_1.1619.1619

Published: 2017

Journal Articles

The Multi-Kinase Inhibitor DCC-2618 Inhibits Proliferation and Survival of Neoplastic Mast Cells and Other Cell Types Involved in Systemic Mastocytosis

Mathias A Schneeweiss, MD, Barbara Peter, DVM, Katharina Blatt, MSc,PhD, Daniela Berger, Gabriele Stefanzl, Emir Hadzijusufovic, DVM, Karoline V Gleixner, MD, Peter Valent, MD

Blood (2016) 128 (22): 1965.

https://doi.org/10.1182/blood.V128.22.1965.1965

Published: 2016

Journal Articles

Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib

Emir Hadzijusufovic, DVM, Rudolf Kirchmair, MD, Markus Theurl, MD, Susanne Gamperl, MSc, Daniela Lener, Clemens Gutmann, Ursula Stanzl, Andrijana Kirsch, MD, Sasa Frank, PhD, Peter Valent, MD

Blood (2016) 128 (22): 1883.

https://doi.org/10.1182/blood.V128.22.1883.1883

Published: 2016

Journal Articles

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

Blood (2016) 128 (22): 396.

https://doi.org/10.1182/blood.V128.22.396.396

Published: 2016

Journal Articles

Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+ MPN Cells

Alexandra Keller, MSc, Barbara Peter, DVM, Johannes Zuber, MD PhD, Philipp Bernhard Staber, MD PhD, Peter Bettelheim, MD, Peter Valent, MD, Emir Hadzijusufovic, DVM

Blood (2015) 126 (23): 2829.

https://doi.org/10.1182/blood.V126.23.2829.2829

Published: 2015

Journal Articles

Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML

Blood (2014) 124 (21): 1800.

https://doi.org/10.1182/blood.V124.21.1800.1800

Published: 2014

Journal Articles

Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms

Ghaith Wedeh, Emir Hadzijusufovic, DVM, Sabine Cerny-Reiterer, D.V.M, Harald Herrmann, M.D., Katharina Blatt, MSc, Ph.D., Gregor Eisenwort, M.D., Ph.D, Gregor Hoermann, M.D., Ph.D., Wolfgang R Sperr, M.D., Leonhard Müllauer, M.D., Christopher R. Vakoc, M.D., Ph.D., James E Bradner, MD, Hans-Peter Horny, MD, Michael Willmann, D.V.M., Johannes Zuber, MD, Michel Arock, PharmD, Ph.D, Peter Valent

Blood (2013) 122 (21): 3747.

https://doi.org/10.1182/blood.V122.21.3747.3747

Published: 2013

Journal Articles

Identification Of The Ki-1 Antigen (CD30) As a Novel Marker and Potential Therapeutic Target In Neoplastic Mast Cells In Advanced Systemic Mastocytosis

Katharina Blatt, MSc, Ph.D., Sabine Cerny-Reiterer, D.V.M, Karl Sotlar, M.D., Schwaab Juliana, M.D., Gregor Hoermann, M.D., Ph.D., Matthias Mayerhofer, M.D., Emir Hadzijusufovic, DVM, Michael Willmann, D.V.M., Andreas Reiter, MD, Hans-Peter Horny, MD, Peter Valent

Blood (2013) 122 (21): 3773.

https://doi.org/10.1182/blood.V122.21.3773.3773

Published: 2013

Journal Articles

KIT D816V Mutation Burden Predicts Prognosis and Survival In Patients With Mastocytosis and Correlates With The WHO Type Of The Disease

Gregor Hoermann, M.D., Ph.D., Karoline V. Gleixner, M.D., Graziella E. Dinu, B.Sc., Georg Greiner, Friedrich Wimazal, M.D., Emir Hadzijusufovic, DVM, Gerlinde Mitterbauer, M.D., Christine Mannhalter, Ph.D., Peter Valent, Wolfgang R Sperr, M.D.

Blood (2013) 122 (21): 4052.

https://doi.org/10.1182/blood.V122.21.4052.4052

Published: 2013

Journal Articles

Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML

Emir Hadzijusufovic, DVM, Susanne Herndlhofer, Karl J. Aichberger, MD, PhD, Viviane Ghanim, M.D., Verena Suppan, BSc, Sabine Cerny-Reiterer, D.V.M., Wolfgang R Sperr, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 2753.

https://doi.org/10.1182/blood.V118.21.2753.2753

Published: 2011

Journal Articles

5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells,

Viviane Ghanim, M.D., Harald Herrmann, MD, Emir Hadzijusufovic, DVM, Barbara Peter, D.V.M., Katharina Blatt, M.Sc., Karina Schuch, Sabine Cerny-Reiterer, D.V.M., Irina Mirkina, PhD, Gerwin Heller, PhD, Sabine Zöchbauer-Müller, MD, Heidrun Karlic, PhD, Winfried F Pickl, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 3457.

https://doi.org/10.1182/blood.V118.21.3457.3457

Published: 2011

Journal Articles

Ponatinib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest and Apoptosis,

Karoline V. Gleixner, M.D., Katharina Blatt, M.Sc., Barbara Peter, D.V.M., Emir Hadzijusufovic, DVM, Peter Valent, M.D.

Blood (2011) 118 (21): 3497.

https://doi.org/10.1182/blood.V118.21.3497.3497

Published: 2011

Journal Articles

The Midostaurin (PKC412) Metabolite CGP52421 Shows Little Growth-Inhibitory Activity Against Against Neoplastic Mast Cells but Retains Inhibitory Effects on IgE-Dependent Activation and Histamine Release

Barbara Peter, D.V.M., Katharina Blatt, M.Sc., Gabriele Stefanzl, Emir Hadzijusufovic, DVM, Catherine Dutreix, Stefan H Gross, Johannes L Roesel, Peter Valent, M.D.

Blood (2011) 118 (21): 1417.

https://doi.org/10.1182/blood.V118.21.1417.1417

Published: 2011

NARROW

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Distinct Diagnostic and Clinical Features of Bone Marrow Mastocytosis: A Study of the Registry of the European Competence Network on Mastocytosis (ECNM)

Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy

The Multi-Kinase Inhibitor DCC-2618 Inhibits Proliferation and Survival of Neoplastic Mast Cells and Other Cell Types Involved in Systemic Mastocytosis

Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+ MPN Cells

Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML

Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms

Identification Of The Ki-1 Antigen (CD30) As a Novel Marker and Potential Therapeutic Target In Neoplastic Mast Cells In Advanced Systemic Mastocytosis

KIT D816V Mutation Burden Predicts Prognosis and Survival In Patients With Mastocytosis and Correlates With The WHO Type Of The Disease

Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML

5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells,

Ponatinib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest and Apoptosis,

The Midostaurin (PKC412) Metabolite CGP52421 Shows Little Growth-Inhibitory Activity Against Against Neoplastic Mast Cells but Retains Inhibitory Effects on IgE-Dependent Activation and Histamine Release

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only